Finance & Capital Markets

41. Biotech M&A Trends With Allan Shaw 3/21/2022

    On this episode of the Business of Biotech, Allan Shaw waxes on his expectations for mergers, acquisitions, and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. We tackle questions biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups that aren't prepared to take a candidate to the finish line have already conceded a major factor in partnership or buyout negotiations. Don't miss Shaw's advice for startup success in a suddenly tumultuous market.

42. Biotech C-Suite Construction With Allan Shaw 10/13/2024

    Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. If you're growing a biotech in these volatile times, this episode of the Business of Biotech offers veteran insight you won't want to miss.

43. Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil 8/19/2026

    On this week's episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and early-stage biotech companies with a focus on clinical data and differentiation as the key value drivers.

44. A Look Behind, A Look Ahead With Allan Shaw 1/4/2021

    The Business Of Biotech kicks off the new year with an up-close-and-personal talk with biotech investor and CFO extraordinaire Allan Shaw. We talk through last year's ups and downs and do a little prognosticating on what we're feeling bullish about--from unprecedented regulatory action to exciting progress on the cell and gene front--as we head into the new year.

45. Creating Competitive Differentiation With Allan Shaw 9/13/2021

    The biologic therapy market is crowded, and judging by the recent parade of IPOs, competition for investment, mindshare, talent, and ultimately share of market is only getting stiffer. On this week's episode of the Business of Biotech, our friend and biotech business guru Allan Shaw joins us for a foundational conversation on creating competitive differentiation at every stage of biopharma growth. We cover the connections between developmental strategy and the competitive commercial landscape, the moral obligation to differentiate between promise and plausibility, the commoditization of brilliant science, and the necessity to align balanced plans with wild dreams.

46. Investing In Early-Stage Oncology With Yosemite's Dan McHugh 3/26/2026

    On this week's episode of the Business of Biotech, Dan McHugh, head of the investment team at Yosemite, explains the San Francisco VC group's approach to investing in early-stage cancer therapeutics and funding academic research through unrestricted grants.

47. IL-2 Program Profits With Bonum's Drs. John Mulligan And Neela Patel 12/13/2023

    On this week's episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche.

48. Managing Mergers With Sail's Guillaume Pfefer, Ph.D 2/15/2024

    You might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic. 

49. BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience 1/29/2025

    From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way.

50. Fiscal Turnarounds With Protalix's Eyal Rubin 8/30/2023

    Within about five minutes of conversation with Protalix CFO Eyal Rubin, I learned that he doesn’t bite his tongue about the rigors of biotech business and finance management, which is precisely why I’m eager to talk with him on today’s episode of the podcast. From commercialization deals with big pharma to being about $50 million underwater to swatting away the day trading armchair quarterbacks on Stocktwits, Rubin’s seen a few things and he’s developed more than a few opinions.